Investigational drug · Phase 2
GSK3036656
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Tuberculosis.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
7
Any phase or sponsor naming "GSK3036656"
First trial start
2022
Jul 26, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GSK3036656", any sponsor or status.
Conditions studied
As listed on its trial records.
- Tuberculosis
Approved drugs for the same conditions: Tuberculosis · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "GSK3036656" as an intervention, largest first.
- Platform Assessing Regimens and Durations In a Global Multisite Consortium for TBPivotal-lookingRecruiting
University College, LondonAcademic, hospital or other
NCT06114628 · 2,500 participants (planned) · Start Jan 9, 2024 · Primary completion Feb 24, 2027
Drug: Ganfeborole; BTZ-043 and 11 more · For: Pulmonary Tuberculosis
Sites: Chisinau, Moldova; Cape Town, South Africa; George, South Africa · 11 sites in all
- PanACEA - STEP2C -01Pivotal-lookingRecruiting
Michael HoelscherAcademic, hospital or other
NCT05807399 · 390 participants (planned) · Start Apr 14, 2023 · Primary completion Oct 31, 2027
Drug: BTZ-043; Rifampicin and 9 more · For: Pulmonary Tuberculosis; Other Specified Pulmonary Tuberculosis
Sites: Lambaréné, Gabon; Blantyre, Malawi; Maputo, Mozambique · 10 sites in all
GlaxoSmithKlineGSK (GSK)
NCT05382312 · 127 participants · Start Jul 26, 2022 · Primary completion May 27, 2025
Drug: GSK3036656; Bedaquiline and 6 more · For: Tuberculosis
Sites: Bellville, South Africa
GlaxoSmithKlineGSK (GSK)
NCT03557281 · 76 participants · Start Mar 22, 2019 · Primary completion Dec 3, 2021
Drug: GSK3036656; Rifafour e-275 · For: Tuberculosis
Sites: Cape Town, South Africa
- First Time in Human (FTIH) Safety and Pharmacokinetics (PK) Study of GSK3036656 in Healthy SubjectsCompleted
GlaxoSmithKlineGSK (GSK)
NCT03075410 · 30 participants · Start Apr 2, 2017 · Primary completion Aug 4, 2017
Drug: GSK3036656; Placebo · For: Tuberculosis
Sites: London, United Kingdom · 2 sites in all
GlaxoSmithKlineGSK (GSK)
NCT07784894 · 28 participants (planned) · Start Aug 20, 2026 · Primary completion Nov 17, 2026
Drug: Ganfeborole; Microgynon · For: Tuberculosis
Sites: Madrid, Spain
GlaxoSmithKlineGSK (GSK)
NCT06354257 · 20 participants · Start Apr 5, 2024 · Primary completion Jul 1, 2024
Drug: Microgynon; GSK3036656 · For: Tuberculosis
Sites: Madrid, Spain
Newest research
PubMed records naming it or its code names, newest first.
- Selectivity of the Time-Dependent M. tuberculosis LeuRS Inhibitor Ganfeborole Is Driven by Target Vulnerability.
Wang M, He Y, Cohen SA, et al. · ACS Chem Biol 2025
- [Annual progress of new drugs and new regimens for anti-tuberculosis treatment (2024)].
Yao L, Tang SJ · Zhonghua Jie He He Hu Xi Za Zhi 2025
- A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial.
Diacon AH, Barry CE, Carlton A, et al. · Nat Med 2024
- First-Time-in-Human Study and Prediction of Early Bactericidal Activity for GSK3036656, a Potent Leucyl-tRNA Synthetase Inhibitor for Tuberculosis Treatment.
Tenero D, Derimanov G, Carlton A, et al. · Antimicrob Agents Chemother 2019
- Discovery of a Potent and Specific M. tuberculosis Leucyl-tRNA Synthetase Inhibitor: (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656).
Li X, Hernandez V, Rock FL, et al. · J Med Chem 2017
Also in development for Tuberculosis
- BCGPhase 38 trials
ImmunityBio, Inc. · Non-muscle Invasive Bladder Cancer (NMIBC), Papillary-Only Non-muscle-invasive Bladder Cancer, Tuberculosis
- MTBVACBBV169Phase 32 trials
Biofabri, S.L · Tuberculosis, Tuberculosis (TB)
- TB-PPDPurified Protein Derivative of TuberculinPhase 32 trials
Chengdu CoenBiotech Co., Ltd · Tuberculosis, Latent Tuberculosis Infection
- DelamanidPhase 22 trials
WestVac Biopharma Co., Ltd. · Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis
- BNT164a1Phase 21 trial
BioNTech SE · Tuberculosis
- BNT164b1Phase 21 trial
BioNTech SE · Tuberculosis
- BTZ-043Phase 21 trial
GSK · Tuberculosis
- JDB0131Phase 21 trial
WestVac Biopharma Co., Ltd. · Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.